C-reactive protein level predicts 30-day mortality and bleeding in patients with venous thromboembolism: A prospective single-center study

Demelo‐Rodríguez, Pablo; Galeano‐Valle, Francisco; Marcelo-Ayala, Almudena; Carracedo, Eduardo Fernández; Cuenca-Zarzuela, Alicia; Gómez-Morales, Marina; Álvarez‐Sala‐Walther, Luis Antonio; Bellón-Cano, José María; Del-Toro-Cervera, Jorge

doi:10.1016/j.medcli.2019.09.024

Cited by 7 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between CRP levels and prognosis in VTE patients could reflect an unspecific general severe condition [58]. This may be supported by the results of other studies demonstrating a similar prognostic role of CRP in acute infections [38], heart failure, or coronary disease [63].…”

Section: C-reactive Protein (Crp)mentioning

confidence: 55%

“…They concluded that both were potential biomarkers for the risk of VTE recurrence after anticoagulation discontinuation (HR: 9.8 (1.9-52) and 5.8 (1.1-31.7) for CPR and D-dimer, respectively). The previously mentioned study by Demelo-Rodríguez et al [58] included 84 patients with CAT and showed that CRP levels were not associated with bleeding in this subgroup.…”

Section: C-reactive Protein (Crp)mentioning

confidence: 79%

“…In another study by Hogg et al [57], CRP levels did not correlate to mortality in patients with VTE. Finally, in a recent prospective study by Demelo-Rodríguez et al [58] on 586 patients with acute VTE (276 with acute PE), a cut-off point of 5 mg/dL for CRP on admission was associated with an increased risk for 30-day bleeding and mortality, in both the total sample and the subgroup of patients with PE, being independent of the simplified Pulmonary Embolism Severity Index (sPESI) and the European Society of Cardiology (ESC) score. This cut-off point improved their predictive capacity when combined with them.…”

Section: C-reactive Protein (Crp)mentioning

confidence: 93%

“…Six studies [53][54][55][56][57][58] have assessed the prognostic role of CRP in patients with PE. All of them were prospective and five of them measured CRP at diagnosis; however, the population size was highly heterogeneous, ranging from 35 to 276 patients, they pursued different objectives (mortality, VTE recurrence, or right ventricular (RV) dysfunction), and the followup periods were quite variable, ranging from 1 to 36 months.…”

Section: C-reactive Protein (Crp)mentioning

confidence: 99%

“…However, CRP remained similar to the control population after the first month, whereas both P-selectin and D-dimer could rise after the withdrawal of anticoagulation therapy, perhaps reflecting a prothrombotic state. The study by Demelo-Rodriguez et al [58] included 358 patients with DVT. CRP levels measured at diagnosis were associated with 30-day mortality and 30-day bleeding risk in the total sample.…”

Section: C-reactive Protein (Crp)mentioning

confidence: 99%

See 4 more Smart Citations

Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review

Galeano‐Valle

Ordieres‐Ortega

Oblitas

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients.

show abstract

Section: C-reactive Protein (Crp)mentioning

confidence: 55%

Section: C-reactive Protein (Crp)mentioning

confidence: 79%